SA
SUPN icon

SRH Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

SRH Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-150
Closed -$4K – 316
2020
Q2 		$4K Hold
150
– – 0.01% 224
2020
Q1 		$3K Hold
150
– – 0.01% 226
2019
Q4 		$4K Sell
150
-400
-73% -$9.71K 0.01% 211
2019
Q3 		$15K Hold
550
– – 0.05% 140
2019
Q2 		$18K Buy
+550
New +$18.8K 0.06% 129

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SRH Advisors's SUPN Position: Q3 2020 in Review

SRH Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2020, closing a stake of 150 shares — an estimated $4K sold.

SRH Advisors first reported a position in SUPN in Q2 2019 and held it in 5 quarters. The position peaked at $18K in Q2 2019. 209 funds tracked by Wall St. Rank hold SUPN as of Q3 2020.

  • SRH Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • SRH Advisors sold 150 Supernus Pharmaceuticals shares in Q3 2020, an estimated $4K.
  • SRH Advisors first reported a position in Supernus Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • SRH Advisors's Supernus Pharmaceuticals position peaked at $18K in Q2 2019.
  • 209 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2020.

Based on SRH Advisors's 13F filing for Q3 2020, filed 21 Oct 2020.